MRVI Maravai LifeSciences Holdings

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.

On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in a fireside chat at the Stifel Healthcare Conference in New York, NY.

On November 21, 2024, at 2:00 a.m. PST/ 9:00 a.m. GMT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London, England.

A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences website, under , . An archived version of the webcast will also be available on the Maravai website after the event is completed.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

For more information about Maravai LifeSciences, visit .



Contact Information:

Investor Contact:
Deb Hart
Maravai LifeSciences
 
 
EN
12/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE

Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Maravai LifeSciences Reports Second Quarter 2025 Financial Results Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted EBITDA and Positive Free Cash Flow expected by second half 2026 SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life s...

 PRESS RELEASE

Maravai LifeSciences To Host Earnings Conference Call on Monday, Augus...

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025 SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conf...

 PRESS RELEASE

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Offic...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  “We thank Kevin for his commitment to Maravai and his...

 PRESS RELEASE

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

 PRESS RELEASE

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch